Literature DB >> 21994083

Abnormal vascular function in PR-interval prolongation.

Yap-Hang Chan1, Chung-Wah Siu, Kai-Hang Yiu, Sheung-Wai Li, Kui-Kai Lau, Tai-Hing Lam, Chu-Pak Lau, Hung-Fat Tse.   

Abstract

BACKGROUND: Underlying mechanisms of PR-interval prolongation leading to increased risk of adverse cardiovascular outcomes, including atrial fibrillation, are unclear. This study aims to investigate the relation between PR interval and changes in vascular function. HYPOTHESIS: We hypothesize that there exists an intermediate pathological stage between electrocardiographic PR prolongation and adverse cardiovascular outcomes, which could be reflected by changes in surrogate measurements of vascular function.
METHODS: We recruited 88 healthy subjects (mean age 57.5 ± 9.8 y, 46% male) from a community-based health screening program who had no history of cardiovascular disease or diabetes mellitus. PR interval was determined from a resting 12-lead electrocardiogram. Vascular function was noninvasively assessed by flow-mediated dilation (FMD) using high-resolution ultrasound and brachial-ankle pulse wave velocity (PWV) using a vascular profiling system.
RESULTS: Only 3 subjects had a PR-interval length longer than the conventional cutoff of 200 ms. The PR-interval length was associated inversely with FMD (Pearson r = -0.30, P = 0.004) and positively with PWV (r = 0.40, P < 0.001). Adjusting for potential confounders, increased PR-interval length by each 25 ms was independently associated with reduced FMD by -1 unit (absolute %, B = -0.04 [95% confidence interval: -0.080 to -0.002, P = 0.040)] and increased PWV by +103 cm/second (B = +4.1 [95% confidence interval: 0.6-7.6, P = 0.023]).
CONCLUSIONS: This study shows that PR-interval length, even in the conventionally normal range, is independently associated with endothelial dysfunction and increased arterial stiffness in healthy subjects free of atherosclerotic disease. This suggests the presence of a systemic, intermediate pathologic stage of the vasculature in PR prolongation before clinically manifest cardiovascular events, and could represent a mediating mechanism.
© 2011 Wiley Periodicals, Inc.

Entities:  

Mesh:

Year:  2011        PMID: 21994083      PMCID: PMC6652440          DOI: 10.1002/clc.20958

Source DB:  PubMed          Journal:  Clin Cardiol        ISSN: 0160-9289            Impact factor:   2.882


  5 in total

1.  Osteogenic circulating endothelial progenitor cells are linked to electrocardiographic conduction abnormalities in rheumatic patients.

Authors:  Yap-Hang Chan; Michael Cheong Ngai; Yan Chen; Mei-Zhen Wu; Yu-Juan Yu; Zhe Zhen; Kevin Lai; Tommy Cheung; Lai-Ming Ho; Ho-Yin Chung; Chak-Sing Lau; Chu-Pak Lau; Hung-Fat Tse; Kai-Hang Yiu
Journal:  Ann Noninvasive Electrocardiol       Date:  2019-04-24       Impact factor: 1.468

2.  Prolongation of PR interval is associated with endothelial dysfunction and activation of vascular repair in high-risk cardiovascular patients.

Authors:  Yap-Hang Chan; Chung-Wah Siu; Kai-Hang Yiu; Yuen-Fung Yiu; Kui-Kai Lau; Tai-Hing Lam; Chu-Pak Lau; Hung-Fat Tse
Journal:  J Interv Card Electrophysiol       Date:  2013-02-07       Impact factor: 1.900

3.  PR interval prolongation in coronary patients or risk equivalent: excess risk of ischemic stroke and vascular pathophysiological insights.

Authors:  Yap-Hang Chan; Jo Jo Hai; Kui-Kai Lau; Sheung-Wai Li; Chu-Pak Lau; Chung-Wah Siu; Kai-Hang Yiu; Hung-Fat Tse
Journal:  BMC Cardiovasc Disord       Date:  2017-08-24       Impact factor: 2.298

4.  Heart rate-adjusted PR as a prognostic marker of long-term ventricular arrhythmias and cardiac death in ICD/CRT-D recipients.

Authors:  Yu-Qiu Li; Shuang Zhao; Ke-Ping Chen; Yang-Gang Su; Wei Hua; Si-Lin Chen; Zhao-Guang Liang; Wei Xu; Yan Dai; Xiao-Han Fan; Shu Zhang
Journal:  J Geriatr Cardiol       Date:  2019-03       Impact factor: 3.327

5.  Cumulative Rheumatic Inflammation Modulates the Bone-Vascular Axis and Risk of Coronary Calcification.

Authors:  Yap-Hang Chan; Michael Cheong Ngai; Yan Chen; Mei-Zhen Wu; Yu-Juan Yu; Zhe Zhen; Kevin Lai; Tommy Cheung; Lai-Ming Ho; Ho-Yin Chung; Chak-Sing Lau; Hung-Fat Tse; Kai-Hang Yiu
Journal:  J Am Heart Assoc       Date:  2019-06-04       Impact factor: 5.501

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.